Agilent Technologies Inc. (Santa Clara, California) has agreed to support research by Steven Gross, a faculty member in the Department of Pharmacology at Weill Cornell Medical College (New York, New York), into amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease.
Agilent Technologies Inc. (Santa Clara, California) has agreed to support research by Steven Gross, a faculty member in the Department of Pharmacology at Weill Cornell Medical College (New York, New York), into amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease. Agilent will provide the latest mass spectrometry technology to support this research, which aims to achieve an understanding of how the most common form of this disease develops in the body.
Gross is an internationally recognized expert in the use of mass spectrometry-based metabolomics. His expertise is in pharmacology and cell biology, particularly in relation to the role of nitric oxide as a signaling molecule. Through the partnership, Agilent will provide two mass spectrometers for Gross’s laboratory.
Sporadic amyotrophic lateral sclerosis (sALS) accounts for about 90 percent of all ALS cases and has no obvious genetic driver. Gross and his collaborators-Giovanni Manfredi, a professor of neuroscience in the Feil Family Brain and Mind Research Institute at Weill Cornell, and Lorenz Studer, director of Sloan Kettering Institute’s Center for Stem Cell Biology-are investigating the molecular underpinnings of this form of ALS. The Agilent tools will assist the investigators in applying a multi-disciplinary-based approach to understanding the roots of this disease. Specifically, accurate-mass spectrometry will enable the researchers to test the hypothesis that fibroblasts express systemic metabolic markers that inform ALS.
Inside the Laboratory: The Gionfriddo Group at the University of Buffalo
March 28th 2024In this edition of “Inside the Laboratory,” Emanuela Gionfriddo, PhD, an associate professor of chemistry at the University at Buffalo, discusses her group’s current research endeavors, including using solid-phase microextraction (SPME) coupled to liquid chromatography (LC) and gas chromatography (GC) to further understand the chemical relationship between environmental exposure and disease and elucidate micropollutants fate in the environment and biological systems.
Transferring Methods to Compact and Portable HPLC
February 14th 2024The current trend in laboratory equipment design is the miniaturization of laboratory instruments. Smaller-scale HPLC instruments offer benefits that cannot be matched by analytical-scale equipment, especially in the areas of portability, reduced fluid volumes, and reduced operating costs. Yet, the miniaturization of laboratory equipment has brought with it a unique set of challenges, including transferring methods to compact LC. Capillary LC expands the use of LC to applications not currently done using conventional LC in a wide array of application areas, including pharmaceutical, food and beverage, petrochemical, environmental, and oil and gas. Greg Ward, Axcend’s CEO wrote, “Customers want an HPLC system with a small footprint, low flow rates and green chemistry.” Join his podcast where he shares method transfer in these application areas.
Sustainable Green Solvents in Microextraction: A Review of Recent Advancements
March 27th 2024Conventional sample preparation can be time- and resource-consuming, and a green analytical methodology can be a game-changer for scientists, in addition to facilitating selective and sensitive separations.